BIAF
bioAffinityANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-17
Current thesis
Q2 CyPath Lung sales acceleration, repeat physician utilization, and expanding clinical validation could support a credible commercialization inflection if growth persists and federal or clinical adoption develops.
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite.
What can break
Clinical validation, military collaboration, and pipeline programs carry execution and adoption risk.
Momentum
100
Value
41
Sentiment
53
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $0.80 · Bull $1.20 · Bear $0.40
Data freshness
Prices
As of 2026-07-17
Fundamentals
As of 2026-07-14 • Vendor: Data Vendor v1
Scores
As of 2026-07-17 • Model: HYBRID_IC_RP
AI Memo
As of 2026-07-14 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-17
Investment thesis
As of 2026-07-17
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Why
Momentum100 · Δ7d -
Value41 · Δ7d -0.1
Sentiment53 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
100
26% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
0.0
Sentiment
53
34% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade A. Momentum 99.9 / Value 41.1 / Sentiment 53.0
Fundamentals (TTM)As of 2026-07-14
Fundamentals (TTM)
As of 2026-07-14
Market Cap
$4.46M
Beta
2.44
Shares Out
6.28M
P/E (TTM) · Derived
-0.1
P/S (TTM)
0.83
P/FCF (TTM) · Derived
-0.10
Rev YoY
-27.1%
EPS YoY
-83.5%
Gross Margin
+24.9%
Op Margin
-153.2%
Net Debt
-$5.29M
Current Ratio
1.36
As of 2026-07-17 • Updated nightlySource: Internal modelMethodology